aristeromycin
design
dualtarget
antivir
compound
aim
inhibit
viral
rnadepend
rna
polymeras
rdrp
host
cell
sadenosyllhomocystein
sah
hydrolas
would
indirectli
target
cap
viral
rna
introduct
fluorin
enhanc
inhibit
sah
hydrolas
activ
rna
virus
adenosin
n
methyladenosin
analogu
show
potent
inhibit
sah
hydrolas
adenosin
deriv
exhibit
potent
antivir
activ
test
rna
virus
middl
east
respiratori
syndromecoronaviru
merscov
sever
acut
respiratori
syndromecoronaviru
chikungunya
viru
andor
zika
viru
show
strongest
antivir
effect
merscov
log
reduct
infecti
progeni
titer
viral
load
reduct
assay
phosphoramid
prodrug
also
demonstr
potent
broadspectrum
antivir
activ
possibl
inhibit
viral
rdrp
studi
show
aristeromycin
serv
start
point
develop
broadspectrum
antivir
agent
target
rna
virus
past
year
outbreak
number
emerg
positivestrand
rna
rna
virus
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
chikungunya
viru
chikv
zika
viru
zikv
serious
threaten
human
health
substanti
socioeconom
impact
sarscov
merscov
caus
seriou
respiratori
diseas
fatal
approxim
case
respect
chikv
transmit
mosquito
caus
pain
arthriti
persist
month
zikv
also
transmit
mosquito
although
sexual
transmiss
occur
well
viru
usual
caus
mild
diseas
caus
neurolog
complic
adult
fetal
death
sever
complic
includ
microcephali
infant
women
infect
pregnanc
chikv
zikv
caus
massiv
outbreak
total
million
infect
past
decad
current
effect
chemotherapeut
agent
vaccin
prevent
cure
infect
four
seriou
pathogen
aforement
virus
belong
rna
viru
group
baltimor
class
iv
indic
genom
rna
polar
mrna
directli
translat
host
ribosom
upon
releas
cytoplasm
host
cell
infect
genom
virus
translat
polyprotein
subsequ
cleav
individu
protein
viral
andor
host
proteas
nonstructur
protein
nsp
virus
harbor
varieti
enzymat
activ
requir
replic
viral
rna
invari
includ
rnadepend
rna
polymeras
rdrp
enzym
present
uninfect
cell
rdrp
transcrib
genom
rna
complementari
negativestrand
rna
subsequ
serv
templat
synthesi
new
positivestrand
rna
mani
rna
virus
includ
coronavirus
chikv
zikv
also
encod
methyltransferas
mtase
requir
methyl
viral
mrna
cap
structur
cap
crucial
stabil
translat
viral
rna
evas
host
innat
immun
respons
viral
mtase
consid
promis
target
develop
antivir
therapi
inhibit
mtase
indirectli
achiev
inhibit
sadenosyllhomocystein
sah
hydrolas
sah
hydrolas
catalyz
interconvers
sah
adenosin
lhomocystein
inhibit
enzym
lead
accumul
sah
cell
turn
inhibit
sadenosyllmethionin
sam
depend
transmethylas
reaction
feedback
inhibit
viral
mtase
depend
sam
methyl
donor
compound
target
cellular
protein
might
exhibit
broader
spectrum
activ
less
like
lead
drugresist
higher
likelihood
toxic
compound
specif
aim
viral
protein
expect
less
cytotox
might
narrow
spectrum
antivir
activ
might
lower
barrier
antivir
drugresist
thu
approach
target
cellular
protein
sah
hydrolas
consid
promis
strategi
develop
broadspectrum
antivir
agent
number
compound
report
act
sah
hydrolas
inhibitor
type
inhibitor
act
inactiv
nad
cofactor
inhibitori
effect
catalyt
activ
enzym
revers
addit
excess
nad
type
ii
inhibitor
irrevers
inhibitor
sah
hydrolas
form
coval
bond
amino
acid
residu
activ
site
enzym
irrevers
inhibit
revers
addit
nad
adenosin
dialysi
viral
rdrp
host
sah
hydrolas
critic
viru
replic
aim
design
broadspectrum
nucleosid
analogu
inhibitor
could
directli
target
rdrp
activ
andor
indirectli
inhibit
methyl
viral
rna
effect
host
sah
hydrolas
modifi
nucleosid
usual
taken
cell
via
nucleosid
transport
success
convert
mono
di
triphosph
cellular
kinas
modifi
nucleosid
triphosph
ntp
compet
natur
ntp
rna
synthesi
incorpor
nascent
viral
rna
lead
chain
termin
detriment
mutat
aristeromycin
natur
occur
carbocycl
nucleosid
origin
identifi
metabolit
streptomyc
citricolor
first
synthesi
racem
report
clayton
cowork
asymmetr
synthes
sinc
report
type
sah
hydrolas
inhibitor
exhibit
potent
antivir
activ
mani
virus
howev
could
advanc
clinic
develop
cytotox
compound
found
toxic
low
concentr
adenosin
kinaseposit
ak
ak
cell
ak
cell
presum
kill
form
toxic
ak
cell
caus
howev
compound
also
metabol
triphosph
form
observ
exert
varieti
metabol
effect
aim
use
prototyp
design
dualtarget
compound
intend
directli
inhibit
viral
rdrp
indirectli
inhibit
cap
process
target
cellular
sah
hydrolas
sinc
introduct
fluorin
carbocycl
nucleosid
known
affect
biolog
activ
signific
extent
aim
synthes
analogu
introduc
fluorin
figur
prisb
cowork
report
synthesi
aristeromycin
inhibitori
activ
sah
hydrolas
synthesi
biolog
activ
report
despit
fact
structur
claim
patent
thu
set
synthes
analogu
optic
pure
dform
biolog
activ
gener
attribut
one
enantiom
disom
yin
cowork
report
eleg
synthesi
optic
pure
biolog
activ
report
synthet
rout
involv
key
intermedi
synthes
employ
n
fluorin
azid
tri
dimethylamino
sulfur
trimethylsilyl
difluorid
wherea
current
approach
includ
stereoselect
electrophil
fluorin
silyl
enol
ether
selectfluor
fluorin
sourc
addit
adenosin
analogu
aim
inhibit
sah
hydrolas
andor
rdrp
also
synthes
purin
pyrimidin
nucleosid
chang
b
structur
figur
could
interfer
viral
rna
synthesi
target
viral
rdrp
phosphoryl
cellular
kinas
bypass
first
ratelimit
step
also
synthes
phosphoramid
prodrug
nucleosid
use
mcguigan
protid
herein
report
synthesi
analogu
preliminari
character
effect
sever
rna
virus
provid
insight
relationship
sar
chemistri
synthesi
target
nucleosid
key
fluorosugar
synthes
dribos
via
electrophil
fluorin
shown
scheme
dribos
convert
dcyclopentenon
accord
previous
publish
procedur
addit
gilman
reagent
yield
dcyclopentanon
deriv
treatment
lithium
hexamethyldisilazid
lihmd
follow
trap
triethylsilyl
chlorid
tescl
gave
silylenol
ether
treat
octan
bi
tetrafluorobor
selectfluor
dimethylformamid
dmf
yield
ratio
articl
stereochemistri
fluorin
confirm
h
noe
experi
irradi
gave
noe
effect
indic
configur
noe
effect
observ
experi
case
confirm
configur
configur
fluorin
confirm
xray
crystal
structur
obtain
convert
final
uracil
deriv
scheme
electrophil
fluorin
condit
yield
equilibr
form
gemin
diol
presenc
electroneg
fluorin
atom
electrophil
fluorin
electrophil
fluorin
nfluorobenzenesulfonimid
nfsi
nfluoroobenzenedisulfonimid
nfob
problemat
result
low
yield
mani
side
spot
reduct
sodium
borohydrid
nabh
lithium
borohydrid
libh
meoh
result
product
deriv
deriv
obtain
minor
isom
shown
scheme
want
improv
stereoselect
synthesi
use
rubottom
oxid
key
step
illustr
scheme
rubottom
oxid
silylenol
ether
osmium
tetroxid
oso
nmethylmorpholinenoxid
nmo
follow
trap
tbutyldimethylsilyl
chlorid
tbscl
produc
singl
stereoisom
yield
reduct
keton
nabh
gave
alcohol
protect
benzyl
group
give
remov
tbutyldimethylsilyl
tb
group
tetranbutylammonium
fluorid
tbaf
yield
disappoint
treatment
n
ndiethylaminosulfur
trifluorid
dast
gave
desir
product
also
undesir
product
ratio
format
rout
result
direct
n
reaction
fluorid
readili
convert
oxonium
ion
rout
ii
via
particip
neighbor
benzyl
group
attack
exclus
fluorid
less
steric
hinder
yield
undesir
product
rout
iii
howev
product
via
rout
iv
form
steric
effect
tbutyloxymethyl
substitu
avoid
particip
neighbor
group
consid
use
cyclic
sulfat
substrat
electronwithdraw
properti
conform
restraint
best
choic
furthermor
cyclic
sulfat
advantag
util
surrog
epoxid
nucleobas
condens
shown
scheme
regioselect
cleavag
trimethylaluminum
alm
follow
treatment
result
diol
thionyl
chlorid
socl
yield
cyclic
sulfit
scheme
synthesi
reagent
condit
licu
ch
otbu
b
articl
remov
tb
group
treatment
dast
yield
desir
cyclic
sulfit
singl
stereoisom
cyclic
sulfit
oxid
form
cyclic
sulfat
subsequ
condens
anion
howev
result
decomposit
thu
decid
synthes
deriv
accord
scheme
scheme
depict
synthesi
aristeromycin
analogu
compound
treat
triflic
anhydrid
tf
follow
treatment
sodium
azid
give
azido
deriv
catalyt
hydrogen
yield
amino
deriv
respect
start
compound
basebuild
process
treatment
presenc
n
ndiisopropylethylamin
dipea
microwav
radiat
condit
yield
cycliz
diethoxymethyl
acet
presenc
microwav
radiat
produc
deriv
treatment
tbutanol
ammonia
follow
remov
protect
group
acid
condit
yield
respect
structur
compound
confirm
singlecryst
xray
analysi
see
support
inform
treatment
aqueou
methylamin
follow
aqueou
trifluoroacet
acid
tfa
result
n
methylaristeromycin
analogu
respect
amino
deriv
also
convert
pyrimidin
nucleosid
deriv
shown
scheme
treatment
e
isocyan
prepar
react
chlorid
silver
cyanat
benzen
produc
respect
cycliz
h
yield
uridin
deriv
respect
structur
confirm
xray
crystallographi
see
support
inform
scheme
synthes
cytidin
deriv
compound
benzoyl
give
respect
articl
convert
cytidin
deriv
use
convent
threestep
procedur
uracil
phosphoramid
analogu
sofosbuvir
use
clinic
power
antihepat
c
viru
agent
therefor
also
synthes
uracil
phosphoramid
prodrug
adenin
phosphoramid
prodrug
deriv
purin
pyrimidin
nucleosid
analogu
use
mcguigan
protid
prodrug
methodolog
shown
scheme
treat
aceton
acid
condit
give
treatment
ditertbutyl
dicarbon
boc
yield
mixtur
ratio
convert
phosphoramid
prodrug
treat
phosphoramidit
reagent
presenc
tbutylmagnesium
chlorid
treatment
formic
acid
produc
final
product
prodrug
monofluoroand
difluoropyrimidin
deriv
similarli
convert
final
prodrug
inhibit
sah
hydrolas
compound
assay
abil
inhibit
recombin
human
sah
hydrolas
protein
express
escherichia
coli
use
dtnb
coupl
assay
describ
et
al
expect
adenosin
deriv
potent
inhibit
sah
hydrolas
none
pyrimidin
analogu
show
inhibitori
activ
concentr
none
prodrug
exhibit
inhibitori
activ
concentr
result
surpris
adenosin
substrat
sah
hydrolas
among
adenosin
analogu
exhibit
potent
inhibitori
activ
ic
potent
control
ic
howev
ic
less
potent
correspond
analogu
less
activ
compound
indic
stereochemistri
import
inhibitori
activ
interestingli
introduct
two
fluorin
result
ic
slightli
potent
control
inhibitori
activ
seri
rank
follow
order
f
introduct
methyl
group
n
amino
group
result
decreas
inhibitori
activ
ic
addit
methyl
group
n
amino
group
result
increas
inhibitori
activ
ic
result
demonstr
n
methyladenin
adenin
moieti
lead
decreas
inhibitori
activ
antivir
activ
novel
analogu
screen
antivir
activ
articl
varieti
rna
virus
compound
test
antivir
activ
cytopath
effect
cpe
reduct
assay
concentr
prepar
serial
dilut
compound
demonstr
antivir
activ
primari
screen
test
extens
dose
respons
experi
differ
concentr
determin
ec
cytotox
cc
determin
parallel
uninfect
cell
tabl
shown
tabl
adenosin
deriv
exhibit
potent
antivir
activ
rna
virus
purin
n
methyladenin
deriv
pyrimidin
deriv
show
signific
antivir
activ
even
result
suggest
antivir
activ
might
due
indirect
effect
viral
mtase
activ
inhibit
host
sah
hydrolas
inhibit
viral
rdrp
appear
import
mechan
action
compound
studi
detail
result
publish
elsewher
compound
inhibit
merscov
replic
ec
howev
also
rather
cytotox
result
select
index
si
replac
remain
f
result
compound
exhibit
nd
determin
si
cc
ec
b
ec
effect
concentr
inhibit
replic
viru
c
cc
cytotox
concentr
inhibit
replic
normal
cell
ec
indic
antivir
activ
observ
highest
concentr
test
either
protect
compound
toxic
figur
effect
infecti
progeni
chikv
zikv
sarscov
merscov
cell
infect
viru
indic
yaxi
graph
medium
variou
concentr
infecti
progeni
titer
determin
plaqu
assay
n
viabil
noninfect
cell
monitor
use
celltit
nonradioact
cell
prolifer
assay
promega
signific
differ
indic
p
p
p
p
reduct
cytotox
antivir
activ
remain
unchang
ec
si
merscov
compound
also
activ
sarscov
si
suggest
may
broadspectrum
coronaviru
inhibitor
addit
also
inhibit
zikv
replic
ec
si
activ
chikv
ec
compound
show
inhibitori
effect
chikv
zikv
replic
like
due
pleiotrop
cytotox
effect
si
among
phosphoramid
prodrug
adenosin
prodrug
exhibit
signific
broadspectrum
antivir
activ
demonstr
may
inhibit
rdrp
rna
virus
convers
triphosph
form
although
remain
determin
biochem
assay
whether
triphosph
form
affect
rdrp
activ
compound
ec
merscov
sarscov
also
si
therefor
consid
potent
inhibitor
coronaviru
replic
howev
chikv
zikv
ec
valu
respect
good
select
indic
interestingli
prodrug
less
potent
also
much
less
cytotox
parent
compound
unusu
regularli
phosphoramid
potent
parent
drug
phosphoramid
might
slowli
hydrolyz
metabol
enzym
parent
drug
phosphatas
could
inhibit
sah
hydrolas
explain
observ
antivir
effect
viral
load
reduct
assay
perform
compound
infect
cell
chikv
zikv
sarscov
merscov
follow
treatment
differ
concentr
hpi
chikv
hpi
zikv
sarsand
merscov
infecti
progeni
titer
medium
determin
plaqu
assay
figur
treatment
concentr
higher
reduc
infecti
chikv
titer
log
effect
zikv
infecti
progeni
titer
limit
show
log
reduct
sarscov
reduct
infecti
progeni
titer
log
concentr
strongest
antivir
effect
observ
merscov
log
reduct
infecti
progeni
titer
infect
cell
treat
concentr
followup
studi
gain
insight
mode
action
relat
compound
current
ongo
result
publish
elsewher
final
measur
log
p
activ
compound
phmetric
method
use
siriu
instrument
lipophil
major
determin
compound
absorpt
distribut
bodi
penetr
across
biolog
barrier
metabol
excret
measur
log
p
indic
almost
equal
partit
lipid
aqueou
phase
rel
low
log
p
expect
overcom
convert
phosphoramid
synthes
aristeromycin
analogu
design
dualtarget
antivir
compound
aim
inhibit
viral
rdrp
host
sah
hydrolas
electrophil
fluorin
silyl
enol
ether
selectfluor
key
step
synthesi
also
synthes
phosphoramid
prodrug
determin
whether
would
inhibit
viru
replic
effect
viral
rna
polymeras
figur
depict
summar
sar
synthes
final
nucleosid
analogu
concern
inhibit
human
sah
hydrolas
inhibit
replic
variou
rna
virus
cap
genom
discov
introduct
fluorin
increas
inhibitori
activ
sah
hydrolas
replic
select
rna
virus
compar
compound
aristeromycin
analogu
potent
inhibit
sah
hydrolas
activ
replic
merscov
sarscov
zikv
chikv
among
compound
potent
ic
sah
hydrolas
activ
ec
merscov
replic
correl
inhibit
sah
hydrolas
antivir
activ
compound
suggest
latter
mainli
due
indirect
target
viral
methyl
reaction
sar
studi
lack
antivir
effect
sever
purin
pyrimidin
analogu
suggest
antivir
effect
unlik
due
target
viral
rdrp
compound
appear
interest
compound
develop
evalu
broadspectrum
antivir
agent
inhibit
sever
coronavirus
chikv
zikv
detail
biolog
studi
efficaci
compound
virusinfect
cell
mode
action
current
ongo
publish
elsewher
chemic
synthesi
gener
method
proton
h
carbon
c
nmr
spectra
obtain
bruker
av
mhz
bruker
amx
mhz
jeol
mhz
bruker
avanc
iii
mhz
spectromet
chemic
shift
report
part
per
million
rel
solvent
peak
coupl
constant
j
report
hertz
mass
spectra
record
thermo
lcq
xp
instrument
optic
rotat
determin
jasco
iii
appropri
solvent
uv
spectra
record
made
hitachi
methanol
water
infrar
spectra
record
ftir
made
biorad
melt
point
determin
buchan
instrument
uncorrect
crude
compound
purifi
column
chromatographi
silica
gel
kieselgel
mesh
merck
element
analys
c
h
n
use
determin
puriti
synthes
compound
result
within
calcul
valu
confirm
puriti
oxi
triethylsilan
cool
solut
mg
mmol
anhydr
tetrahydrofuran
thf
ml
dropwis
ad
chlorotriethylsilan
ml
mmol
follow
addit
lihmd
ml
solut
thf
mmol
n
stir
temperatur
min
reaction
mixtur
quench
satur
aqueou
nh
cl
ml
layer
separ
aqueou
layer
extract
ethyl
acet
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
mg
colorless
oil
ch
tertbutyl
cool
solut
silyl
enol
ether
g
mmol
anhydr
dmf
ml
ad
octan
bi
tetrafluorobor
g
mmol
selectfluor
one
portion
n
stir
temperatur
h
reaction
mixtur
quench
satur
aqueou
nh
cl
ml
dilut
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
g
total
yield
h
nmr
analysi
compound
gener
procedur
synthesi
cool
solut
equiv
meoh
sodium
borohydrid
lithium
borohydrid
ad
singl
portion
n
atmospher
stir
min
temperatur
reaction
mixtur
neutral
acet
acid
ml
evapor
residu
dilut
satur
aqueou
nh
cl
aqueou
layer
extract
etoac
ml
combin
organ
layer
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
tertbutoxymethyl
r
r
r
r
e
r
b
u
x
e
h
l
e
r
tbutyldimethylsilyl
oxi
one
cool
solut
mg
mmol
anhydr
thf
ml
ad
noxid
monohydr
mg
mmol
equiv
osmium
tetroxid
mg
mmol
equiv
n
atmospher
stir
min
reaction
mixtur
ad
sodium
thiosulf
pentahydr
mg
sodium
sulfit
mg
aceton
ml
stir
addit
h
temperatur
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
h
follow
satur
brine
dri
anhydr
mgso
filter
evapor
residu
use
next
step
without
purif
solut
gener
intermedi
anhydr
dmf
ml
ad
tbscl
mg
mmol
imidazol
mg
mmol
n
atmospher
stir
h
room
temperatur
reaction
mixtur
quench
satur
aqueou
nh
cl
ml
dilut
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
articl
give
mg
colorless
syrup
ch
tertbutyl
ch
tertbutyl
h
found
c
h
r
r
r
r
e
r
b
u
x
e
h
l
e
r
tbutyldimethylsilyl
oxi
cool
solut
mg
mmol
methanol
ml
ad
sodium
borohydrid
mg
mmol
equiv
n
atmospher
stir
temperatur
h
reaction
mixtur
dilut
h
ml
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
benzyloxi
tertbutoxymethyl
oxi
tertbutyl
dimethylsilan
cool
solut
mg
mmol
dmf
ml
ad
benzyl
chlorid
ml
mmol
equiv
sodium
hydrid
mg
mmol
equiv
n
atmospher
stir
room
temperatur
h
reaction
mixtur
dilut
h
ml
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
mg
colorless
syrup
benzyloxi
tertbutoxymethyl
dioxol
cool
solut
mg
mmol
anhydr
toluen
ml
dropwis
ad
diethylaminosulfur
trifluorid
mmol
equiv
n
atmospher
stir
room
temperatur
h
reaction
mixtur
quench
satur
aqueou
nh
cl
ml
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
mg
mg
colorless
syrup
tertbutoxi
tertbutoxymethyl
dioxathiol
perform
regioselect
cleavag
cool
solut
mg
mmol
anhydr
ch
cl
ml
dropwis
ad
trimethylaluminum
ml
solut
hexan
mmol
equiv
n
atmospher
stir
room
temperatur
h
reaction
mixtur
quench
satur
aqueou
nh
cl
ml
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
diol
intermedi
mg
colorless
syrup
introduct
cyclic
sulfit
cool
solut
diol
intermedi
mg
mmol
anhydr
ch
cl
ml
dropwis
ad
triethylamin
ml
mmol
equiv
follow
thionyl
chlorid
mmol
n
atmospher
stir
room
temperatur
min
reaction
mixtur
quench
satur
aqueou
nh
cl
ml
dilut
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
flash
column
chromatographi
silica
gel
hexanesetoac
give
cyclic
sulfit
intermedi
mg
colorless
syrup
articl
tb
deprotect
cool
solut
mg
mmol
anhydr
thf
ml
ad
acet
acid
ml
mmol
equiv
follow
tbaf
solut
ml
solut
thf
mmol
equiv
n
atmospher
stir
room
temperatur
h
reaction
mixtur
quench
h
ml
dilut
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
mg
two
diastereom
b
gener
sulfoxid
stereogen
center
colorless
syrup
h
nmr
mhz
cdcl
j
hz
j
hz
dd
j
hz
j
hz
dd
j
hz
c
nmr
mhz
cdcl
tertbutoxi
tertbutoxymethyl
dioxathiol
cool
solut
mg
mmol
anhydr
ch
cl
ml
dropwis
ad
diethylaminosulfur
trifluorid
mmol
equiv
n
atmospher
stir
room
temperatur
h
reaction
mixtur
quench
satur
aqueou
nh
cl
ml
dilut
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
flash
column
chromatographi
silica
gel
hexanesetoac
give
mg
colorless
syrup
j
hz
j
hz
j
hz
ch
tertbutyl
ch
tertbutyl
tertbutoxi
tertbutoxymethyl
dioxathiol
solut
cyclic
sulfit
mg
mmol
ccl
ch
cnh
total
ml
ad
one
portion
sodium
period
mg
mmol
follow
ruthenium
iii
chlorid
trihydr
mg
mmol
room
temperatur
n
atmospher
stir
temperatur
min
reaction
mixtur
quench
h
ml
dilut
ch
cl
ml
layer
separ
aqueou
layer
extract
ch
cl
ml
combin
organ
layer
wash
success
h
satur
brine
dri
anhydr
mgso
filter
evapor
crude
product
use
next
step
without
purif
gener
procedur
synthesi
triflat
cool
solut
equiv
anhydr
pyridin
trifluoromethanesulfon
anhydrid
equiv
ad
dropwis
n
atmospher
stir
temperatur
min
reaction
mixtur
quench
h
ml
dilut
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
satur
aqueou
cuso
follow
water
dri
anhydr
mgso
filter
evapor
residu
use
next
step
without
purif
azid
solut
triflat
intermedi
equiv
anhydr
dmf
sodium
azid
equiv
ad
singl
portion
room
temperatur
heat
stir
h
reaction
mixtur
cool
room
temperatur
quench
h
ml
dilut
etoac
ml
layer
separ
aqueou
layer
extract
etoac
ml
combin
organ
layer
wash
h
follow
satur
brine
dri
anhydr
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexanesetoac
give
tertbutoxymethyl
n
found
c
h
n
gener
procedur
synthesi
suspens
equiv
methanol
palladium
activ
carbon
equiv
ad
stir
overnight
room
temperatur
h
atmospher
filtrat
solvent
remov
residu
use
next
step
without
purif
gener
procedur
synthesi
solut
equiv
nbutanol
pyrimidin
equiv
diisopropylamin
equiv
ad
reaction
mixtur
place
microwav
irradi
h
solvent
coevapor
meoh
residu
purifi
column
chromatographi
silica
gel
hexaneetoac
give
respect
n
found
c
h
n
n
tertbutoxymethyl
obtain
yield
yellow
foam
h
n
found
c
h
n
gener
procedur
synthesi
solut
diethoxymethyl
acet
place
microwav
irradi
h
mixtur
coevapor
meoh
three
time
result
residu
purifi
column
chromatographi
silica
gel
hexaneetoac
give
tertbutoxymethyl
obtain
yield
yellow
foam
c
ch
cl
h
nmr
mhz
cdcl
j
hz
j
hz
j
hz
j
hz
c
nmr
mhz
cdcl
j
hz
j
hz
j
hz
j
hz
ch
tertbutyl
f
nmr
mhz
cdcl
clfn
c
h
n
found
c
h
n
tertbutoxymethyl
obtain
yield
yellow
foam
c
meoh
h
nmr
mhz
cdcl
dt
j
hz
j
hz
j
hz
j
hz
j
hz
j
hz
j
hz
clfn
c
h
n
found
c
h
n
tertbutoxymethyl
j
hz
dd
j
hz
j
hz
j
hz
dd
j
hz
j
hz
j
hz
h
n
found
c
h
n
gener
procedur
synthesi
solut
tertbutanol
ml
contain
stainless
steel
bomb
reactor
satur
ammonia
tertbutanol
ml
ad
reactor
lock
heat
stir
h
mixtur
cool
room
temperatur
coevapor
meoh
without
purif
residu
ad
tfah
solut
vv
total
ml
heat
stir
h
reaction
mixtur
evapor
residu
purifi
column
chromatographi
silica
gel
ch
cl
meoh
give
hydroxymethyl
cyclopentan
dt
j
ddd
j
hz
dd
j
hz
dd
j
hz
c
nmr
mhz
cd
od
j
hz
j
hz
j
hz
h
n
found
c
h
n
hydroxymethyl
cyclopentan
obtain
yield
white
solid
mp
c
meoh
h
nmr
mhz
cd
od
ddd
j
hz
ddd
j
hz
dd
j
hz
j
hz
c
nmr
mhz
cd
od
j
hz
j
hz
j
hz
j
hz
j
h
n
found
c
h
n
hydroxymethyl
cyclopentan
j
hz
dd
j
hz
j
hz
j
hz
dd
j
hz
j
hz
j
hz
h
n
found
c
h
n
gener
procedur
synthesi
solut
mmol
etoh
ml
seal
glass
tube
methylamin
wt
h
ml
ad
stir
room
temperatur
h
mixtur
concentr
ad
tfah
solut
vv
total
ml
without
purif
heat
stir
h
reaction
mixtur
evapor
residu
purifi
column
chromatographi
silica
gel
ch
cl
meoh
give
articl
hydroxymethyl
methylamino
cyclopentan
n
found
c
h
n
hydroxymethyl
methylamino
n
found
c
h
n
gener
procedur
synthesi
cool
solut
equiv
dmf
isocyan
equiv
benzen
ad
dropwis
n
atmospher
reaction
mixtur
slowli
warm
room
temperatur
h
stir
reaction
mixtur
filter
ch
cl
coevapor
toluen
ethanol
residu
purifi
column
chromatographi
silica
gel
hexaneetoac
give
e
n
tertbutoxymethyl
j
hz
j
hz
j
stir
solut
ml
sulfur
acid
ml
dropwis
ad
reflux
stir
h
reaction
mixtur
cool
room
temperatur
neutral
dowex
ionexchang
resin
mixtur
filter
evapor
residu
purifi
column
chromatographi
silica
gel
ch
cl
meoh
give
h
f
n
c
h
n
found
c
h
n
gener
procedur
synthesi
benzoyl
cool
solut
equiv
ch
cl
benzoyl
chlorid
equiv
pyridin
equiv
ad
n
atmospher
stir
h
room
temperatur
reaction
mixtur
quench
h
extract
ch
cl
organ
layer
combin
wash
h
follow
brine
dri
mgso
filter
evapor
residu
purifi
column
chromatographi
silica
gel
hexaneetoac
give
benzoyl
intermedi
introduct
triazol
cool
suspens
equiv
anhydr
mecn
phosphoryl
chlorid
equiv
ad
dropwis
n
atmospher
stir
benzoyl
intermedi
equiv
mecn
follow
trimethylamin
equiv
ad
reaction
mixtur
addit
stir
room
temperatur
h
reaction
mixtur
evapor
reaction
mixtur
dilut
ch
cl
articl
h
layer
separ
organ
layer
wash
h
dri
mgso
filter
evapor
amin
seal
glass
tube
abovegener
intermedi
ad
excess
satur
aqueou
ammonia
room
temperatur
stir
temperatur
h
reaction
mixtur
evapor
purifi
flash
chromatographi
silica
gel
ch
cl
meoh
give
benzoyl
protect
cytosin
intermedi
benzoyl
deprotect
seal
glass
tube
abovegener
benzoylprotect
cytosin
intermedi
meoh
ad
satur
ammonia
meoh
stir
temperatur
reaction
mixtur
evapor
dilut
h
ch
cl
layer
separ
h
layer
wash
ch
cl
time
evapor
give
respect
h
fix
cell
formaldehyd
absorb
measur
nm
berthold
mithra
lb
plate
reader
valu
express
rel
uninfect
infect
untreat
viabil
sampl
result
repres
averag
quadrupl
sampl
express
mean
sd
compound
found
protect
evalu
cpe
reduct
assay
test
differ
concentr
determin
ec
previous
describ
cytotox
cc
compound
determin
parallel
experi
perform
quadrupl
graphpad
prism
use
ec
cc
determin
nonlinear
regress
viral
load
reduct
assay
chikv
zikv
cell
seed
densiti
cellswel
ml
fc
cell
cultur
plate
allow
adher
overnight
merscov
sarscov
cell
densiti
cellswel
vero
vero
cell
use
respect
condit
describ
next
day
compound
dilut
prepar
fc
viru
ad
yield
inocula
infect
cell
moi
chikv
moi
zikv
moi
sarsand
merscov
cell
incub
inoculum
h
chikv
sarsand
merscov
h
zikv
infect
cell
wash
twice
mlwell
warm
phosphatebuff
salin
mlwell
fresh
fc
differ
concentr
compound
ad
cell
incub
h
chikv
h
zikv
sarsand
merscov
supernat
harvest
store
determin
infecti
viru
titer
plaqu
assay
viabil
assay
conduct
parallel
describ
previou
paragraph
plaqu
assay
chikv
sarscov
cell
merscov
vero
cell
zikv
vero
cell
perform
describ
previous
compound
test
concentr
duplic
two
independ
experi
n
graphpad
prism
use
statist
analysi
oneway
anova
multipl
comparison
test
jsi
gk
contribut
equal
work
author
contribut
manuscript
given
approv
final
version
manuscript
